AtriCure (ATRC) Stock Price, News & Analysis

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1-year target prices for AtriCure's stock. Their ATRC share price targets range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $55.57 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC stock has decreased by 34.3% and is now trading at $23.45.
View the best growth stocks for 2024 here.

AtriCure saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,250,000 shares, an increase of 9.4% from the March 15th total of 2,970,000 shares. Based on an average daily trading volume, of 668,700 shares, the days-to-cover ratio is currently 4.9 days.
View AtriCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ATRC earnings forecast.

AtriCure will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Thursday, February, 15th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to analysts' expectations of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 7.55%. The company's revenue was up 21.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.09) EPS.

ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).iShares U.S. Medical Devices ETF (IHI).

AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of -0.820--0.740 for the period, compared to the consensus estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure's stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.